Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 1 to 10 of 65 total matches.
Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression ...
The FDA has approved trilaciclib (Cosela – G1
Therapeutics), a cyclin-dependent kinase (CDK) 4/6
inhibitor, to decrease the incidence of chemotherapy-induced
myelosuppression in adults receiving a
platinum/etoposide- or topotecan-containing regimen
for extensive-stage small cell lung cancer
(ES-SCLC). Trilaciclib is the first myeloprotective drug
to be approved in the US for administration before
chemotherapy.
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously
called Rolontis), a granulocyte colony-stimulating
factor (G-CSF) conjugated to an Fc fragment of human
IgG4, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4 doi:10.58347/tml.2023.1677b | Show Introduction Hide Introduction
Tremelimumab (Imjudo) for Metastatic NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
-based chemotherapy for treatment of
metastatic non-small cell lung cancer (NSCLC) in
adults ...
The FDA has approved tremelimumab-actl (Imjudo –
AstraZeneca), a cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4) blocking antibody, for use in
combination with the programmed death-ligand 1
(PD-L1) blocking antibody durvalumab (Imfinzi)
and platinum-based chemotherapy for treatment of
metastatic non-small cell lung cancer (NSCLC) in
adults with no sensitizing epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK) genomic tumor aberrations.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e31-2 doi:10.58347/tml.2023.1669h | Show Introduction Hide Introduction
Ryzneuta for Prevention of Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia. It is
the first ...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a
nonpegylated granulocyte colony-stimulating factor
(G-CSF) conjugated to an Fc fragment of human
IgG2, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia. It is
the first nonpegylated, long-acting G-CSF to become
available in the US. Two pegylated, long-acting
G-CSFs, pegfilgrastim (Neulasta, and biosimilars)
and eflapegrastim (Rolvedon), are...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5 doi:10.58347/tml.2024.1709d | Show Introduction Hide Introduction
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did ...
The FDA has approved tislelizumab (Tevimbra –
BeiGene), a programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did not include a programmed death ligand-1
(PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6 doi:10.58347/tml.2024.1702h | Show Introduction Hide Introduction
Cemiplimab (Libtayo) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
chemotherapy than with
chemotherapy alone (21.9 vs 13.0 months). Median
progression-free survival was 8.2 ...
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) in adults with no
epidermal growth factor receptor (EGFR), anaplastic
lymphoma kinase (ALK), or ROS1 aberrations and
who are not candidates for surgical resection or
chemoradiation. The drug was previously approved
for first-line treatment of NSCLC in patients whose
tumors have high PD-L1 expression and no genomic
tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8 doi:10.58347/tml.2023.1674e | Show Introduction Hide Introduction
Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
or GEJ adenocarcinoma, addition of zolbetuximab to
standard chemotherapy extended progression-free ...
Zolbetuximab-clzb (Vyloy – Astellas), a claudin
18.2 (CLDN18.2)-directed cytolytic antibody, has
been approved by the FDA for use in combination
with fluoropyrimidine- and platinum-containing
chemotherapy for first-line treatment of locally
advanced unresectable or metastatic human epidermal
growth factor receptor 2 (HER2)-negative gastric or
gastroesophageal junction (GEJ) adenocarcinoma in
patients who have CLDN18.2-positive tumors. It is the
first monoclonal antibody to be approved in the US
that selectively targets CLDN18.2.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e204-5 doi:10.58347/tml.2024.1717g | Show Introduction Hide Introduction
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease ...
The FDA has approved datopotamab deruxtecan
(Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast
cell-surface antigen-2 (Trop-2)-directed antibody
and topoisomerase inhibitor conjugate, for treatment
of adults with unresectable or metastatic hormone
receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative breast cancer who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2 doi:10.58347/tml.2025.1723e | Show Introduction Hide Introduction
In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
neoadjuvant or
adjuvant chemotherapy. The drug was previously
approved for treatment of adults ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has been
approved by the FDA for adjuvant treatment of adults
with deleterious or suspected deleterious germline
BRCA-mutated (gBRCAm), human epidermal growth
factor receptor 2 (HER2)-negative, high-risk early
breast cancer who received prior neoadjuvant or
adjuvant chemotherapy. The drug was previously
approved for treatment of adults with deleterious
or suspected deleterious gBRCAm, HER2-negative
metastatic breast cancer who received chemotherapy
in the neoadjuvant, adjuvant, or metastatic...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e77-8 doi:10.58347/tml.2023.1674j | Show Introduction Hide Introduction